此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

测试在原发性 CNS 淋巴瘤的常规治疗中加入来那度胺和纳武单抗

2026年11月11日 更新者:National Cancer Institute (NCI)

甲氨蝶呤、利妥昔单抗、来那度胺和纳武单抗 (Nivo-MR2) 诱导后继以来那度胺和纳武单抗维持治疗原发性中枢神经系统淋巴瘤的 I 期试验

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents to improve response. This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction).

研究概览

详细说明

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with high dose-methotrexate (HD-MTX) and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma.

II. Determine the proportion of patients who are able to stay on maintenance therapy with lenalidomide and/or nivolumab for 6 months after induction treatment of primary CNS lymphoma.

SECONDARY OBJECTIVES:

I. To evaluate the overall response rate (ORR) of the combination of methotrexate, rituximab, lenalidomide, nivolumab.

II. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on progression free survival (PFS).

III. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To analyze tumor tissue and cerebrospinal fluid (CSF) for gene expression profiles, and to correlate these profiles with treatment outcomes.

II. To determine whether CSF proteome and metabolome are predictors of outcomes (prognostic marker).

III. To assess response to therapy and minimal residual disease via MRI-based metrics and minimal residual disease of blood and CSF.

IV. To evaluate the relationship between neurocognitive deficits and tumor and brain volumetrics, as assessed by magnetic resonance imaging (MRI) and tumor metabolism.

OUTLINE: This is a dose-escalation study of lenalidomide.

INDUCTION: Patients receive rituximab intravenously (IV) on day 1, methotrexate IV over 2 hours or orally (PO) on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.

MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo magnetic resonance imaging (MRI) throughout the trial, computed tomography (CT) and positron emission tomography (PET)/CT during screening, and lumbar puncture at the end of the 6th cycle of induction, and after 6 months of maintenance. Patients may also undergo bone marrow aspirate and biopsy, testicular ultrasound and/or echocardiogram (ECHO) during screening.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for up to 2 years.

研究类型

介入性

注册 (估计的)

47

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90048
        • Cedars-Sinai Medical Center
      • San Francisco、California、美国、94143
        • UCSF Medical Center-Parnassus
    • Florida
      • Coral Gables、Florida、美国、33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach、Florida、美国、33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Doral、Florida、美国、33166
        • UM Sylvester Comprehensive Cancer Center at Doral
      • Miami、Florida、美国、33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami、Florida、美国、33176
        • UM Sylvester Comprehensive Cancer Center at Kendall
      • North Miami、Florida、美国、33181
        • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
      • Plantation、Florida、美国、33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
    • Iowa
      • Ankeny、Iowa、美国、50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Carroll、Iowa、美国、51401
        • Saint Anthony Regional Hospital
      • Clive、Iowa、美国、50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines、Iowa、美国、50309
        • Iowa Methodist Medical Center
      • Des Moines、Iowa、美国、50314
        • Mercy Medical Center - Des Moines
      • Des Moines、Iowa、美国、50314
        • Broadlawns Medical Center
      • Des Moines、Iowa、美国、50316
        • Iowa Lutheran Hospital
      • Des Moines、Iowa、美国、50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines、Iowa、美国、50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge、Iowa、美国、50501
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
      • Iowa City、Iowa、美国、52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Waukee、Iowa、美国、50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
      • West Des Moines、Iowa、美国、50266-7700
        • Methodist West Hospital
    • Louisiana
      • Baton Rouge、Louisiana、美国、70805
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge、Louisiana、美国、70808
        • Our Lady of the Lake Physician Group
    • Maine
      • Portland、Maine、美国、04102
        • MaineHealth Maine Medical Center - Portland
      • Scarborough、Maine、美国、04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland、Maine、美国、04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Michigan
      • Adrian、Michigan、美国、49221
        • Hickman Cancer Center
      • Monroe、Michigan、美国、48162
        • Toledo Clinic Cancer Centers-Monroe
    • Missouri
      • City of Saint Peters、Missouri、美国、63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur、Missouri、美国、63141
        • Siteman Cancer Center at West County Hospital
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
      • St Louis、Missouri、美国、63129
        • Siteman Cancer Center-South County
      • St Louis、Missouri、美国、63136
        • Siteman Cancer Center at Christian Hospital
    • New Jersey
      • Summit、New Jersey、美国、07902
        • Overlook Hospital
    • New York
      • Lake Success、New York、美国、11042
        • Northwell Health/Center for Advanced Medicine
      • Manhasset、New York、美国、11030
        • North Shore University Hospital
      • New York、New York、美国、10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York、New York、美国、10065
        • NYP/Weill Cornell Medical Center
      • Syracuse、New York、美国、13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • UNC Lineberger Comprehensive Cancer Center
    • Ohio
      • Columbus、Ohio、美国、43210
        • Ohio State University Comprehensive Cancer Center
      • Toledo、Ohio、美国、43623
        • Toledo Clinic Cancer Centers-Toledo
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • University of Oklahoma Health Sciences Center
    • Rhode Island
      • Providence、Rhode Island、美国、02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
    • Texas
      • Dallas、Texas、美国、75390
        • UT Southwestern/Simmons Cancer Center-Dallas
    • Utah
      • Salt Lake City、Utah、美国、84112
        • Huntsman Cancer Institute/University of Utah
    • West Virginia
      • Morgantown、West Virginia、美国、26506
        • West Virginia University Healthcare
    • Wisconsin
      • Eau Claire、Wisconsin、美国、54701
        • Marshfield Medical Center-EC Cancer Center
      • La Crosse、Wisconsin、美国、54601
        • Gundersen Lutheran Medical Center
      • Marshfield、Wisconsin、美国、54449
        • Marshfield Medical Center-Marshfield
      • Minocqua、Wisconsin、美国、54548
        • Marshfield Medical Center - Minocqua
      • Rice Lake、Wisconsin、美国、54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point、Wisconsin、美国、54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Weston、Wisconsin、美国、54476
        • Marshfield Medical Center - Weston

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically proven primary CNS diffuse large b-cell lymphoma confirmed by one of the following:

    • Brain biopsy or resection
    • Cerebrospinal fluid
    • Vitreous fluid
  • No prior organ transplantation to exclude post-transplant lymphoproliferative disorders

  • No prior chemotherapy or radiation therapy for lymphoma

  • No prior allogeneic stem cell transplantation

  • Use of systemic corticosteroids (dexamethasone up to 24 mg/day or equivalent) for disease control or improvement of performance status to be tapered as fast as clinically safe after initiation of therapy is permissible

  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, female of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) =< 7 days prior to registration

  • Age >= 18 years

  • Karnofsky performance scale (KPS) >= 40 (>= 50 for patients older than 60 unless related to lymphoma on investigator's opinion)

  • Absolute neutrophil count (ANC) >= 1,500/mm^3

  • Platelet count >= 100,000/mm^3

  • Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault formula

  • Total Bilirubin =< 1.5 x upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)

  • No evidence of non-Hodgkin's lymphoma (NHL) outside CNS

  • No prior history of NHL

  • No history of autoimmune disorder. Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as Systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

  • Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)

  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (except short course of systemic corticosteroids for disease control or improvement of performance status) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted

  • Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study

  • No prior or concurrent malignancies with exception of surgically cured carcinoma in situ (CIS) of the uterus, carcinoma of the skin without evidence of disease for >= 5 years

  • No concurrent malignancy requiring active therapy

  • No untreated hepatitis C virus (HCV) infection with detectable HCV viral load

  • No untreated chronic hepatitis B virus (HBV) infection with detectable HBV viral load

  • No untreated human immunodeficiency virus (HIV) infection or with detectable viral load or with CD4+T-cell count of less than 500/mm^3

  • No history of HIV infection and evidence of Epstein Barr virus (EBV)-related primary central nervous system lymphoma (PCNSL)

  • Inability to tolerate anticoagulation with acetylsalicylic acid, warfarin, or direct oral anticoagulants

  • No other investigational agent

  • No history of severe hypersensitivity reaction to any monoclonal antibody

  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in study

  • Sulfonamide drugs, trimethoprim, salicylates, nonsteroidal anti-inflammatory drugs, penicillin, vitamin C, ciprofloxacin, and proton pump inhibitors should be held at least 48 hours prior to methotrexate administration

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (rituximab, methotrexate, lenalidomide, nivolumab)

INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.

MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo MRI, CT, PET/CT, lumbar puncture, bone marrow aspirate and biopsy, testicular ultrasound and ECHO. (See Detailed Description)

Given PO

其他名称:
  • CC-5013
  • 来那度胺
  • CC5013
  • 疾控中心 501
  • CC 5013

Given IV

其他名称:
  • 利妥昔单抗
  • 美罗华
  • 总部基地 798
  • BI 695500
  • C2B8单克隆抗体
  • 嵌合抗 CD20 抗体
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8单克隆抗体
  • 单克隆抗体IDEC-C2B8
  • PF-05280586
  • 里亚布尼
  • 利妥昔单抗ABBS
  • 利妥昔单抗ARRX
  • 利妥昔单抗生物类似药 ABP 798
  • 利妥昔单抗生物仿制药 BI 695500
  • 利妥昔单抗生物类似药 CT-P10
  • 利妥昔单抗生物类似药 GB241
  • 利妥昔单抗生物仿制药 IBI301
  • 利妥昔单抗生物类似药 JHL1101
  • 利妥昔单抗生物仿制药 PF-05280586
  • 利妥昔单抗生物类似药 RTXM83
  • 利妥昔单抗生物仿制药 SAIT101
  • 利妥昔单抗生物仿制药 SIBP-02
  • 利妥昔单抗生物类似药 TQB2303
  • 利妥昔单抗PVVR
  • 利妥昔单抗-arrx
  • 利妥昔单抗-pvvr
  • RTXM83
  • Ruxience
  • 特鲁希玛
  • 里克松
  • 伊克达尔
  • 马布塔斯
  • 利妥昔单抗-abbs
  • BI-695500
  • BI695500
  • 闪电战
  • IDEC 102
  • IDEC102
  • PF 05280586
  • PF05280586
  • 里特维亚
  • 利妥昔单抗-blit
  • 利西名
  • RTXM 83
  • RTXM-83
  • ABP-798
  • ABP798
  • CT P10
  • CTP10
  • 2013年大奖赛
  • GP-2013
  • GP2013
  • 利妥昔单抗生物仿制药 GP2013

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo ECHO

其他名称:
  • 超声心动图
  • 欧共体

Given IV

其他名称:
  • BMS-936558
  • MDX-1106
  • 尼沃
  • ONO-4538
  • 欧狄沃
  • CMAB819
  • Nivolumab 生物类似药 CMAB819
  • MDX 1106
  • MDX1106
  • 电池管理系统 936558
  • 总部血压206
  • 纳武单抗生物仿制药 ABP 206
  • BCD-263
  • 纳武单抗生物仿制药 BCD-263
  • BMS936558
  • 小野4538

Undergo lumbar puncture

其他名称:
  • 唱片
  • 脊柱穿刺

Undergo PET/CT

其他名称:
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • PT
  • 正电子发射断层扫描(程序)

Undergo CT and PET/CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo bone marrow aspirate and biopsy

Given IV or PO

其他名称:
  • 阿比曲沙
  • 福莱克斯
  • 梅赛特
  • 甲氨蝶呤
  • 甲氧蝶呤
  • 氨甲蝶呤
  • 溴甲磺酸
  • CL 14377
  • CL-14377
  • Emtexate
  • 艾美泰
  • 消融剂
  • 农美曲沙
  • Fauldexato
  • 福莱克斯全氟辛烷磺酸
  • 兰塔雷尔
  • 莱德曲沙
  • Lumexon公司
  • 麦克斯曲斯
  • 美泰克斯
  • 美白素
  • 甲氨蝶呤LPF
  • 甲氨蝶呤甲氨蝶呤
  • 美特捷
  • Mexate-AQ
  • 诺瓦特雷克斯
  • 风湿曲
  • 得克萨斯
  • 混纺
  • 曲克塞隆
  • 三锡林
  • WR-19039
  • 吉拉姆沃

Undergo testicular ultrasound

其他名称:
  • 超音波
  • 二维灰度超声成像
  • 二维超声成像
  • 二维美国
  • 超声波测试
  • 超声波,医疗
  • 我们
  • 超声检查

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum tolerated dose
大体时间:During the first 14-day cycle of treatment

Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). The number and severity of all adverse events will be tabulated and summarized in this patient population both overall and by dose level according to the Common Terminology Criteria for Adverse Events (CTCAE) Cancer Therapy Evaluation Program version 5.0 criteria. The grade 3+ adverse events will also be described and summarized in a similar fashion. This will provide an indication of the level of tolerance for this treatment combination in this patient group.

During the first 14-day cycle of treatment
Proportion of evaluable patients who are able to stay on maintenance therapy
大体时间:Up to 6 months

The proportion of evaluable patients who meet the criteria for maintenance feasibility, along with the 95% exact binomial confidence interval, will be provided.

Up to 6 months

次要结果测量

结果测量
措施说明
大体时间
Overall response
大体时间:Up to 5 years

Will be estimated by the number of patients with the objective status of complete response, unconfirmed complete response, or partial response divided by the total number of evaluable patients. The overall response rate with an exact binomial 95% confidence interval will be provided and will be analyzed at the end of induction therapy and again after all therapy (induction and maintenance).

Up to 5 years
Progression free survival (PFS)
大体时间:Time from start of induction treatment to progression or death due to any cause

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). PFS time from start of maintenance therapy will also be reported in a similar fashion as the PFS time starting from induction therapy.

Time from start of induction treatment to progression or death due to any cause
Overall Survival (OS)
大体时间:Time from start of induction treatment to death due to any cause

The distribution of overall survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). OS time from start of maintenance therapy will also be reported in a similar fashion as the OS time starting from induction therapy.

Time from start of induction treatment to death due to any cause
Incidence of adverse events
大体时间:Up to 5 years

Toxicity will be measured by the CTCAE version 5.0. The maximum grade, frequency, and severity for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration and analyzed descriptively.

Up to 5 years

其他结果措施

结果测量
措施说明
大体时间
Minimal residual disease (MRD)
大体时间:Up to 5 years

Will estimate the proportion of patients with MRD at each time point with 95% confidence intervals. Will also use swimmer plots and other graphical analyses to visualize when MRD is detected/not detected in sequential samples relative to progression of disease.

Up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alvaro J Alencar、Alliance for Clinical Trials in Oncology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月24日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2020年10月29日

首先提交符合 QC 标准的

2020年10月29日

首次发布 (实际的)

2020年10月30日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅